

Vita Life Sciences Limited

ACN 003 190 421

ABN 35 003 190 421

Corporate Office

1/102 Bath Road,
Kirrawee NSW 2232

P.O. Box 3143

Kirrawee NSW 2232

T/Free: 1800 852 222

T: 02 9545 2633

F: 02 9545 1311

vitalifesciences.com

13 June 2024

Market Announcements
Australian Securities Exchange Ltd
20 Bridge Street
Sydney, NSW 2000

GUIDANCE

Vita Life Sciences (ASX: VLS) announces the following guidance for the half year ending 30 June 2024:

Sales: \$39.0m-\$40.0m (*H1 2023: \$34.7m*)

Pre-tax Profit: \$5.5m-6.0m (*H1 2023: \$5.5m*)

The Company remains confident in maintaining revenue growth across its core markets in Australia, Malaysia and Singapore. First-half performance has been buoyed by robust sales, reflecting the strength of the Group's diverse product portfolio and effective channel strategies.

Group operations continue to track against expectations. Looking ahead, there will be a continued focus on investment in trade and brand advertising, aligned with evolving channel dynamics.

Management remains positive in delivering ongoing shareholder value and returns.



Andrew O'Keefe
Managing Director

Email: enquiries@vitalifesciences.com.au